The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Scenesse label, and added the Drugs@FDA approval record. 12
What this version reported
Two smaller randomized, vehicle-controlled trials described in the label found more time in direct sunlight on pain-free days than with the vehicle. The label warns of serious allergic reactions and darkening of skin, moles and freckles.↗
Reader guide in this version
Key takeaway
Afamelanotide is a lab-made analogue of alpha-melanocyte-stimulating hormone, the hormone that drives skin pigmentation, and is the active ingredient in Scenesse.1,2 It is FDA-approved for one use: increasing pain-free light exposure in adults with a history of painful light reactions caused by erythropoietic protoporphyria (EPP), a rare inherited condition.1 The approval rests on two smaller randomized trials in which people with EPP spent more time in direct sunlight without pain than with a dummy treatment.1 It is not a tanning or cosmetic product, and the label warns of serious allergic reactions and darkening of moles and freckles.1
At a glance
- What it is
- A synthetic peptide of 13 amino acids modelled on alpha-melanocyte-stimulating hormone. The label describes it as a melanocortin receptor agonist that binds mainly to the MC1 receptor.1
- FDA status
- FDA-approved. Drugs@FDA lists Scenesse with an original approval date of October 8, 2019, and the label limits its use to adults with EPP. The cited label has no boxed warning.1,2
- Human evidence
- Two randomized, vehicle-controlled trials in 93 and 74 people with EPP, described in the label.1
- Evidence strength
- Smaller controlled human trials
What is afamelanotide?
Afamelanotide is a synthetic peptide of 13 amino acids. The label describes it as a structural analogue of alpha-melanocyte-stimulating hormone (α-MSH), the body’s own signal for skin pigmentation.1
In the United States it is the active ingredient of Scenesse, according to Drugs@FDA.2
How does afamelanotide work?
The label states that afamelanotide is a melanocortin receptor agonist that binds mainly to the MC1 receptor, which is found on pigment-producing skin cells.1
The label notes that its pharmacologic effect can increase skin pigmentation generally and darken existing moles and freckles.1
What do human studies show?
The label describes two randomized, vehicle-controlled trials in people with EPP. In Study CUV039, 93 participants were followed for 180 days; the median total time spent in direct sunlight on pain-free days was 64.1 hours with afamelanotide and 40.5 hours with the vehicle.1
In Study CUV029, 74 participants were followed for 270 days; the median time outdoors in mostly direct sunlight on pain-free days was 6.0 hours with afamelanotide and 0.75 hours with the vehicle. The two trials measured sunlight exposure differently.1
Across three controlled trials involving 244 adults with EPP, the most common adverse reactions included reactions where the product was placed, nausea, throat pain, cough, fatigue and skin darkening, according to the label.1
What the evidence base contains
- Controlled human trial Study CUV039 (NCT01605136): a randomized, vehicle-controlled trial in 93 people with EPP, followed for 180 days, that counted hours spent in direct sunlight on days without pain.1
- Controlled human trial Study CUV029 (NCT00979745): a randomized, vehicle-controlled trial in 74 people with EPP, followed for 270 days, with a related sunlight-exposure outcome.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is afamelanotide FDA-approved?
Yes. Drugs@FDA lists Scenesse, application NDA210797, with an original approval date of October 8, 2019.2
The Scenesse label cited here (DailyMed SPL version 11, published May 13, 2026) states that it is indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.1
The label has no boxed warning. It states that afamelanotide is contraindicated in people with a history of severe allergic reactions to it, and reports serious allergic reactions, including anaphylaxis, after approval.1
Its warnings also cover generalized skin darkening and darkening of existing moles and freckles, and the label recommends regular full-body skin examinations.1
What is still unknown?
Its safety and effectiveness in children, which the label says have not been established.1
How the trial results translate into daily life: the two trials recorded sunlight exposure in different ways and time windows.1
Its effects outside EPP: the label covers only adults with this condition.1
Sources for this version
- 1SCENESSE (afamelanotide) implant · SPL version 11 · published 2026-05-13 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA210797 · original submission status AP · 2019-10-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026